Omid Yazdanpanah

ORCID: 0000-0002-5795-461X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Research Studies
  • Pain Mechanisms and Treatments
  • Neuroendocrine Tumor Research Advances
  • Brain Metastases and Treatment
  • Renal cell carcinoma treatment
  • Radiopharmaceutical Chemistry and Applications
  • Neuroscience and Neuropharmacology Research
  • Multiple Myeloma Research and Treatments
  • Neuroblastoma Research and Treatments
  • Management of metastatic bone disease
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Diagnosis and Treatment
  • LGBTQ Health, Identity, and Policy
  • Cancer therapeutics and mechanisms
  • Cancer, Lipids, and Metabolism
  • Primary Care and Health Outcomes
  • Sarcoma Diagnosis and Treatment
  • Testicular diseases and treatments
  • Cancer Genomics and Diagnostics
  • Antioxidant Activity and Oxidative Stress
  • Cancer-related molecular mechanisms research
  • Cancer Diagnosis and Treatment
  • Toxoplasma gondii Research Studies

University of California, Irvine
2023-2025

University of California, Irvine Medical Center
2023-2024

UC Irvine Health
2024

Detroit Medical Center
2020-2022

The Barbara Ann Karmanos Cancer Institute
2021-2022

Wayne State University
2020-2022

John D. Dingell VA Medical Center
2021

Kerman University of Medical Sciences
2015-2017

There is a rising trend in the consumption of dietary supplements, especially among adults, with purpose improving health. While marketing campaigns tout potential health benefits using it critical to evaluate harmful effects associated these supplements as well. The majority scarce research on vitamins focuses acute or chronic toxicities use supplements. Quality still required further investigate risks long-term risk developing cancers. present review concentrates studies that have...

10.3390/cancers16050880 article EN Cancers 2024-02-22

121 Background: In the Phase 3 VISION trial, treatment with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy [ 177 Lu]Lu-PSMA-617 ( Lu-PSMA-617) + protocol-permitted standard of care (SoC) significantly improved median radiographic progression-free survival (rPFS; 8.7 vs 3.4 months [mo]) and overall (OS; 15.3 11.3 mo) in patients metastatic castration-resistant prostate cancer (mCRPC) SoC alone. However, it is unclear how addition androgen receptor pathway inhibitors...

10.1200/jco.2025.43.5_suppl.121 article EN Journal of Clinical Oncology 2025-02-10

696 Background: The treatment landscape for genitourinary (GU) malignancies, including bladder, kidney, and prostate cancers, has evolved with several novel therapies approved in the past decade. importance of mental health patients cancer is being more recognized years. This study evaluates monitoring psychiatric symptoms trials leading to FDA approvals GU cancers. Methods: We comprehensively reviewed trial protocols publications FDA-approved from 2015-2024. For each therapy, we examined...

10.1200/jco.2025.43.5_suppl.696 article EN Journal of Clinical Oncology 2025-02-10

The current standard of care for the treatment small cell lung cancer (SCLC) is concurrent chemoradiation patients with limited-stage SCLC (LS-SCLC) and chemoimmunotherapy extensive-stage (ES-SCLC). backbone chemotherapy regimens in both a platinum-etoposide doublet: cisplatin traditionally preferred platinum agent curative intent setting, whereas carboplatin ES-SCLC because its favorable toxicity profile.To determine whether associated better survival outcomes than treating LS-SCLC...

10.1001/jamanetworkopen.2022.37699 article EN cc-by-nc-nd JAMA Network Open 2022-10-20

Gastroesophageal junction hepatoid adenocarcinoma is a rare form of gastroesophageal cancer. We present case 38-year-old man with no significant medical history who was diagnosed but initially misdiagnosed testicular germ cell tumor, given the elevated alpha-feto protein and poorly differentiated pathology. will elaborate on importance gene expression profiling in modern oncology to better define tumor origin patients cancer unknown primary origin, how it helped us diagnose can help identify...

10.1177/2050313x231223469 article EN cc-by-nc SAGE Open Medical Case Reports 2024-01-01

Background: Pregabalin has shown remarkable antinociceptive effects in neuropathic pain; however, its efficacy against acute and visceral pain remained controversial. Objectives: The present study aimed at investigating the involvement of N-methyl-D-aspartate (NMDA) receptors effect pregabalin both using comparing hot plate test writhing male mice. Methods: NMDA (15 30 mg/kg), as an agonist or MK801 (0.02 0.05 mg/kg) receptor (NMDAR) antagonist, were injected intraperitoneally either alone...

10.5812/aapm.14602 article EN Anesthesiology and Pain Medicine 2017-06-21

Pregabalin as a new anticonvulsant has been used in different pain treatments.The aim of this study was to investigate the role N-methyl-D-aspartate (NMDA) ligands antinociceptive effect pregabalin mice using tail flick.NMDA (15 and 30 mg/kg) an agonist or MK801 (0.02 0.05 antagonist were injected intraperitoneally either alone 15 minutes before dose (100 mg/kg). Then latency times %MPE measured flick assay during 75 minutes.NMDA had no effects alone. NMDA pretreatment significantly...

10.5812/aapm.28968 article EN Anesthesiology and Pain Medicine 2015-10-03

Meigs' syndrome is classically characterized as the triad of ascites, pleural effusion, and ovarian fibroma. The incidence not easily determined but has been described in medical literature. We report a case patient who presented for shortness breath was found to have an mass. Investigative measures were consistent with syndrome; however, definitive diagnosis able be our opted symptomatic treatment rather than pursue surgical options. discuss pathophysiology management pseudo-Meigs'...

10.7759/cureus.9704 article EN Cureus 2020-08-12

e16260 Background: Therapeutic inhibition of constitutive signaling mediated by mutated KRAS in PDAC remains a challenge except for modest success reported with G12C inhibition. A combinatorial strategy utilizing simultaneous MEK and autophagy holds therapeutic promise based on mechanism action preclinical data. We described characteristics outcomes patients (pts) treated MEK-inh HCQ at our institution. Methods: Ten KRAS-mutated advanced pts were trametinib-HCQ (n = 9) or cobimetinib-HCQ 1)...

10.1200/jco.2022.40.16_suppl.e16260 article EN Journal of Clinical Oncology 2022-06-01

We present the case of a 45-year-old man with known history sarcoidosis who presented double vision and headache. On examination, he was found to have left abducens hypoglossal nerve palsy. CT then MRI demonstrated extensive osseous lesions large expansile mass involving clivus bone sphenoid sinus. Laboratory data were remarkable for normocytic anaemia, low anion gap elevated total protein which raised suspicion multiple myeloma. Subsequent electrophoresis immunofixation illustrated...

10.1136/bcr-2020-235725 article EN BMJ Case Reports 2020-08-01

e17064 Background: The VISION study demonstrated improved outcomes with up to 6 doses of 177 -Lu-PSMA plus standard-of-care (SOC) therapy versus SOC alone in pre-treated mCRPC patients, which led its regulatory approval on 03/23/22. This is our real-world experience at the University California, Irvine and Hoag Hospital. Methods: a retrospective analysis 22 patients treated Hospital since 03/23/2022. Baseline demographic, pathologic, genomic characteristics all who received (along their...

10.1200/jco.2024.42.16_suppl.e17064 article EN Journal of Clinical Oncology 2024-06-01

e16581 Background: Management of acute pulmonary embolism (PE) in patients with genitourinary (GU) malignancies is usually challenging. It associated adverse outcomes and can significantly contribute to morbidity mortality detrimentally impacts quality life among cancer patients. There has been scarce previous national population study on PE GU malignancies. Here, we studied the rate readmissions for admitted cancers U.S. its burden health care system. Methods: Utilizing Nationwide...

10.1200/jco.2024.42.16_suppl.e16581 article EN Journal of Clinical Oncology 2024-06-01

e16530 Background: First-line clear cell mRCC management has evolved to include doublet therapies containing either a tyrosine kinase inhibitor (TKI) with an immuno-oncology (IO) agent or two IO agents. Oncologists typically prescribe based on guideline recommendations their personal experience various therapies. However, patient preferences may not be major factor in this decision-making process. Previously published data topic is scarce. This study aimed assess the treatment of and compare...

10.1200/jco.2024.42.16_suppl.e16530 article EN Journal of Clinical Oncology 2024-06-01

A woman in her 40s with no medical history presented on hospital day #0 3 days of epigastric pain, nausea, vomiting and bloody diarrhoea. Initial blood work demonstrated acute kidney injury metabolic acidosis an elevated anion gap, thrombocytopenia, lactate dehydrogenase, undetectable haptoglobin. She was quickly diagnosed haemolytic uraemic syndrome from Shiga toxin-producing O157:H7 Escherichia coli . Her microangiopathic anaemia renal failure progressively worsened only improved after the...

10.1136/bcr-2023-256449 article EN BMJ Case Reports 2024-08-01
Coming Soon ...